The world, in perspective.

The labelling requirement stems from the findings of a 2024 study and subsequent FDA trials that tested the results of that study.

The makers of GLP-1 weight loss drugs such as Ozempic, Wegovy and Mounjaro must add a warning label about a possible link to permanent vision loss , the US Food and Drug Administration has said. The regulator said that it based the decision on research that linked a rare eye condition, called non-arteritic anterior ischemic optic neuropathy (NAION), which ca

FDA inclui alerta sobre perda de visão rara em medicamentos populares da classe GLP-1 Adobe Stock Medicamentos populares para perda de peso, incluindo Ozempic e Wegovy, passarão a trazer um novo alerta sobre um possível efeito colateral raro que, em alguns casos, pode levar à perda permanente da visão, anunciaram as autoridades de saúde dos Estados Unidos ne

The risk appears small and data is mixed, but FDA wants patients to be aware.

Dr. Jon LaPook joins "CBS Mornings" to break down the facts on a new warning about GLP-1 medications causing possible vision loss.

The agency has found evidence of a potential increased risk of a rare eye condition linked to the use of GLP-1 drugs used for weight management and diabetes.

Wer mit GLP-1-Medikamenten wie Ozempic oder Wegovy abnimmt, verliert auch Muskelmasse. Neue Forschungen zeigen, wie groß das Problem wirklich ist.

The FDA announced that GLP-1 weight loss drugs will now include warning labels indicating a potential increased risk of vision loss.

The Food and Drug Administration is adding a new warning about possible rare cases of vision loss reported with GLP-1 drugs like Ozempic, Wegovy and other brands.

Aussie gym is hoping to change the game, launching the nation's first exercise class designed for those using a GLP-1.

<p>Foundayo, a daily pill, successfully reduced obstructive sleep apnea, according to clinical trial data</p>

GLP-1 drugs may increase the risk of NAION, a rare optic nerve condition that can lead to sudden vision loss. It has no known treatment.

Novonesis is exploring whether gut health supplements could benefit patients taking GLP-1 weight-loss drugs, opening up a potentially lucrative new market.

Rapid weight loss can trigger hair loss, heart complications and vitamin deficiencies if nutrient needs go unmet, health experts have warned.

Investigadores analisaram os registos médicos de mais de 256.000 adultos com pré-diabetes e obesidade, dos quais cerca de metade tomava medicamentos à base de GLP-1.

Wegovy’s GLP-1 weight loss tablet has been approved in Australia for the first time, expected to lead to a surge in demand for the sought-after peptide which could hit the market by the end of this year.

Wegovy,&nbsp;a GLP-1 weight-loss drug, is already available in Singapore as a once-weekly weight-loss injection. Now offered as a daily pill in several countries but not Singapore, how does it compare with the jab? Doctors explain its effectiveness, dosing, side effects and why it isn’t meant for casual weight loss.

Coverage of GLP-1 drugs for weight loss is being dropped by many employer-sponsored healthcare plans as premiums soar, though workers have some new options.

Dr. Rachel Pessah-Pollack discusses new guidance from the American College of Obstetricians and Gynecologists on GLP-1 use during pregnancy.

New research on GLP-1 drug usage from EY-Parthenon shows that weight loss is now the most popular use of the drug once dedicated to diabetes patients. CBS News' Megan Cerullo reports on how the drugs are changing spending habits for users.

Growing usage of GLP-1 drugs for weight loss is reshaping how consumers shop for food and clothes, according to consulting firm EY-Parthenon.

Atenta a las nuevas necesidades y preocupaciones que genera el uso cada vez más difundido de los GLP-1, la industria cosmética prueba productos para contrarrestar algunos de los efectos adversos de estos medicamentos

(서울=연합뉴스) 신선미 기자 = 첫 국산 글루카곤 유사 펩타이드-1(GLP-1) 계열 비만 치료제 '에페 오토인젝터주'(에페글레나타이드) 처방...